ImmunoCellular Therapeutics and the Torrey Pines Institute for Molecular Studies have identified peptides that can generate CD-133 T-cells suitable for immunological targeting.

The partners are pursuing additional studies to support regulatory filings for an investigational new drug application and research on cancer stem cell targets.

ImmunoCellular is a clinical-stage biotech company developing immune-based therapies to treat brain and other cancers, while Torrey Pines is a research centre dedicated to basic research.